October 20, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.
The patent (patent number: 10-2592716) will provide an exclusivity period until August 2040, with the possibility of up to 5 years patent term extension upon market approval.
Corresponding patent applications have previously been granted in Europe and Hong Kong and filed in additional strategically important patent territories globally.
For more information:
Jenny Sundqvist, CEO
Phone: +46 8 122 038 50
E-mail: [email protected]
Johan Giléus, Deputy CEO and CFO
Phone: +46 8 122 038 50
E-mail: [email protected]
Publication
The information was submitted for publication through the agency of the contact person set out above at 14:10 CET on October 20, 2023.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III program CONCLUDE as a novel treatment of moderate to severe left-sided ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.
The information in this press release is intended for investors.
